Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2012

View Archived Issues

Imipramine blue with doxorubicin improves survival in glioma model

Positive phase I results presented for Achillion's NS5A inhibitor

Janssen Pharmaceutica designs new series of compounds for pain

Scientists at Antoxis disclose novel antioxidant compounds

XMetA improves experimental hyperglycemia

hMaxi-K gene transfer appears safe in women with overactive bladder

Follow-up of AAV2-FIX study patients shows low risk of insertional mutagenesis

Spanish team discloses new treatments for Huntington's disease

Canadian researchers present new vaccines for influenza

Influenza vaccine triggers protective HAI titers against unmatched H5N1 strains

New treatments for obesity described by Takeda Pharmaceutical

Novel isoflavones discovered at Nanjing University of Technology

Hisamitsu Pharmaceutical seeks approval for transdermal oxybutynin in Japan

Adamas ready to begin phase III studies of memantine/donepezil capsules

Trimel Pharmaceuticals begins enrollment in phase II Tefina trial

PCI Biotech enrolls first patient in phase II ENHANCE study of Amphinex

NovaBay enrolls first patients in phase IIb BAYnovation study

FDA accepts amendment to Northwest's DCVax-L trial in brain cancer

Ambit Biosciences and Teva receive IND clearance for CEP-32496

Spectrum Pharmaceuticals begins Zevalin/motexafin combination study

Urocortin 2 improves cardiac output in acute decompensated heart failure

New phase II trial investigates ladostigil in mild cognitive impairment

Vertex and CCFC fund Canadian research in IBD

Levotofisopam proof-of-concept trial successfully completed

FDA approves new administration schedule for BioThrax

Epodure to begin first U.S. trial for treatment of anemia in dialysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...